Unyango lomhlaza wesibindi eTshayina 2026: Unyango lwamvanje kunye neendleko-izibhedlele ezikufutshane nam 

Unyango lomhlaza wesibindi e-China ngo-2026 luye lwavela kwixesha elichanekileyo, ligxile ekunciphiseni ukuphindaphinda emva kotyando ngobungozi bomngcipheko kunye nonyango oludibeneyo. Umhlaza wesibindi, ngokuyinhloko i-hepatocellular carcinoma (HCC), ngoku ilawulwa ngokusetyenziswa kwe-immunotherapy ephezulu, iziyobisi ezijoliswe kuyo, kunye nokungenelela kwendawo elungiselelwe umngcipheko wokuphindaphinda komntu ngamnye. Imvumelwano yamva nje yeengcaphephe zika-2026 igxininisa ukuchonga izigulana ezisemngciphekweni omkhulu kwangethuba kwaye zisebenzise unyango olucwangcisiweyo olufana ne-PD-1 inhibitors ezidityaniswe nee-anti-angiogenic agents ukuphucula kakhulu amazinga okusinda.

Ukuqonda iNtuthuko yoNyango lweSibindi eTshayina ngo-2026

Imbonakalo yomhlaba ye umhlaza wesibindi ulawulo e-China iye yatshintsha ngokuphawulekayo 2026. Iqhutywa uphando olubanzi lwezonyango kunye nokukhululwa "2026 Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma,"Iiprothokholi zonyango ngoku zenziwe ngabantu kakhulu. Ifilosofi engundoqo iye yasuka kwindlela yokulinganisa yonke into ukuya kwisicwangciso esisekelwe kwi-stratification yengozi echanekileyo.

Ngokwembali, amazinga okuphindaphinda emva kotyando ebephakathi kwama-50% nama-70%. Nangona kunjalo, idatha entsha iphakamisa ukuba ukudibanisa unyango lwenkqubo kunye nokungenelela kwendawo kunokunciphisa kakhulu la manani. Izikhokelo ze-2026 zigxininisa iintlobo ezimbini ezihlukeneyo zokuphindaphinda: ukuphindaphinda kwangaphambili (ngaphakathi kweminyaka emibini) kunye nokuphindaphinda emva kwexesha (emva kweminyaka emibini). Ngamnye ufuna indlela yonyango eyahlukileyo.

Ukuphindaphinda kwangethuba ihlala idityaniswa ne-micro-metastases ekhoyo phambi kotyando okanye ukusasazwa kwe-intraoperative. Ngokwahlukileyo, ukuphindaphinda kade ngokuqhelekileyo isuka kwi-de novo tumors evela ngenxa yesifo esingapheliyo sesibindi, njenge-hepatitis B okanye i-cirrhosis. Ukuqaphela lo mahluko kubalulekile ekukhetheni unyango olufanelekileyo lwe-adjuvant.

Imiba ephambili yoMngcipheko wokuPhinda kwangethuba

Oogqirha ngoku basebenzisa iindlela ezithile zokuchonga izigulane ezifuna unyango lwe-adjuvant ndlongo emva kokuhlinzwa. Ezi zinto zinomngcipheko ophezulu ziquka:

• Ubuninzi beTumor: Ubukho be-tumor nodules ezininzi.
• Ubungakanani beTumor: Ubuninzi bedayamitha engaphezulu kwe-5 cm.
• IBanga loMahluko: Edmondson grade III-IV, ebonisa iiseli ezingahlukiyo kakuhle.
• Uhlaselo lweVascular: I-Microvascular (MVI) okanye i-macrovascular invasion.
• I-Lymph Node Metastasis: Ukusasazeka kwii-lymph nodes zengingqi.
• Ukuqhekeka kwethumba: Imbali yokugqabhuka okuzenzekelayo phambi koqhaqho.
• Amanqanaba eBiomarker: Ukungaqheleki okuthe gqolo kwe-Alpha-fetoprotein (AFP) okanye i-Des-gamma-carboxy prothrombin (DCP) emva kotyando.

Izigulane ezibonisa ezi mpawu zibhekwa njengabaviwa abaphambili kunyango olunzulu lwe-adjuvant, kubandakanywa i-immunotherapy kunye nee-agent ezijoliswe kuzo.

Izinto eziPhembelela ukuPhinda kade

Ukuphindaphinda kade, ugxininiso lutshintsha ekulawuleni isifo sesibindi esingasemva. Abaxhasi abaphambili baquka:

• Ubudala: Izigulane ezingaphezu kweminyaka engama-60 ubudala.
• Umsebenzi weNtsholongwane: I-hepatitis yentsholongwane esebenzayo esebenzayo (HBsAg positive).
• Ubungqongqo beCirrhosis: Amanqaku aphezulu e-Ishak okanye e-Scheuer abonisa i-fibrosis ephezulu.
• I-Hypoalbuminemia: Amanqanaba asezantsi e-albumin e-serum abonisa ukusebenza kakubi kwesibindi.

Ulawulo lweli qela lubeka phambili unyango lwe-antiviral lwexesha elide kunye nokubeka iliso rhoqo ukuthintela ukubunjwa kwethumba elitsha.

Ixesha leNdibaniselwano ekujoliswe kuyo kunye ne-Immunotherapy

Olunye uhlaziyo olubalulekileyo kwizikhokelo ze-2026 ludibaniso olusemthethweni lwe-systemic antitumor therapy kwisimo somncedisi. Oku kuphawula ukungena kwe umhlaza wesibindi unyango ukuya “kwixesha ekujoliswe kulo-immunotherapy.” Ngaphambili, amachiza enkqubo ayegcinelwe iimeko ezihambele phambili, ezingachaswanga. Ngoku, zisetyenziselwa ukuphelisa isifo se-microscopic esishiyekileyo.

Ukunyuka koNyango oluDityanisiweyo

Izilingo zeklinikhi zakutsha nje zibonise ukuba ukudibanisa i-immune checkpoint inhibitors (ICIs) kunye ne-tyrosine kinase inhibitors (TKIs) okanye i-anti-VEGF antibodies ivelisa iziphumo eziphezulu xa kuthelekiswa ne-monotherapy. Irejimeni ye-“T+A” (i-Atezolizumab kunye ne-Bevacizumab) kunye nendibaniselwano yasekhaya efana ne-Donafenib kunye ne-Toripalimab zibonise iziphumo ezithembisayo ekwandiseni ukuPhila-kuKhula kokuSinda okuHlangayo (RFS).

Kwizigulana ezisemngciphekweni omkhulu, i-agent-agent immunotherapy enamachiza afana ne-Sintilimab okanye i-Nivolumab nayo ibonakalise ukusebenza. Ezi arhente zinceda ukuvuselela amajoni omzimba ukuze abone kwaye atshabalalise iiseli zomhlaza eziseleyo. Imvumelwano ka-2026 iphawula ngokuthe ngqo ukuba ezi zonyango azisekho uvavanyo kodwa zicetyiswa iinketho ezisemgangathweni kumaqela afanelekileyo asemngciphekweni.

Ubungqina obuxhasa iiRegimens ezintsha

Idatha ethiwe thaca kwiinkomfa zamva nje zemfundo e-Shanghai ibonisa ukuba inoveli ethile kumachiza ekujoliswe kuyo inokufikelela umlinganiselo wonyaka omnye we-RFS osondela kuma-87% kubantu abasengozini enkulu. Ngaphezu koko, iirejimeni ezidityanisiweyo zezigulane ezinamathumba amakhulu (> 5 cm) kunye ne-MVI ziye zabika amazinga okuphila onyaka omnye ngaphezu kwe-96%. Ezi nkcukacha-manani zibonisa utshintsho olukhulu ukusuka kwiibenchmarks zembali.

Nangona kunjalo, ukusetyenziswa kwala mayeza anamandla kufuna ukukhetha ngokucophelela isigulane. Ayizizo zonke izigulane ezixhamla ngokulinganayo, kwaye amandla okuba neziganeko ezimbi ezinxulumene ne-immune (irAEs) zidinga umgaqo-sikhokelo wokulawula ukhuseleko olomeleleyo.

Unyango lweNdawo: Ukumanyanisa kunye noCongo

Ngelixa unyango lwenkqubo luzuza ukuvelela, unyango lwasekhaya luhlala luyimfuneko kwi-algorithm yonyango ka-2026. Ukuvumelana okuhlaziyiweyo kunika izikhokelo eziphuculweyo malunga nokuba nini kwaye njani ukusetyenziswa kwe-Transarterial Chemoembolization (TACE), i-Hepatic Arterial Infusion Chemotherapy (HAIC), kunye ne-radiotherapy.

IiProtocol ze-Adjuvant TACE

Kwizigulane ezisemngciphekweni omkhulu, i-TACE yoncedo iyacetyiswa malunga nenyanga enye emva koqhaqho loqhaqho. Inkqubo eqhelekileyo ibandakanya ikhosi enye ukuya kwezimbini. Eli xesha livumela isibindi ukuba sichache emva kotyando ngoxa sijolise kuzo naziphi na iimetastases ezisasazwa egazini. I-TACE isebenza ngokunciphisa unikezelo lwegazi kwiiseli eziseleyo zethumba kunye nokuhambisa uxinzelelo oluphezulu lwechemotherapy ngqo esibindini.

I-HAIC ye-Microvascular Invasion

Eyona nto ibalulekileyo yohlaziyo lwe-2026 yingcebiso ethile ye-HAIC kwizigulane ezine-Microvascular Invasion (MVI). Ukusebenzisa i-FOLFOX irejimeni, i-HAIC iboniswe ukuba iphucule kakhulu i-RFS kweli qela. Ngokungafaniyo ne-TACE, edibanisa imithambo, i-HAIC ngokuqhubekayo ifaka ichemotherapy, igcina amanqanaba aphezulu echiza kwizicubu zethumba ezineziphumo ebezingalindelekanga ezimbalwa zenkqubo.

Unyango lweRadio kwiMida emxinwa

Imida yotyando yinto ebalulekileyo yokuphindaphinda. Kwizigulane ezinemida enqamlekileyo ye-resection (≤1 cm), i-MVI enhle, okanye i-portal vein tumor thrombus, i-Intensity-Modulated Radiation Therapy (IMRT) ngoku isisixhobo esibalulekileyo sokuncedisa. I-Radiotherapy icoca ngokufanelekileyo ibhedi ye-tumor, inciphisa umngcipheko wokuphindaphinda kwendawo. Ixabiseke ngakumbi xa utyando olongezelelweyo lungenakwenzeka.

ULawulo oluBanzi kunye neSiseko se-Antiviral

Isivumelwano se-2026 sigxininisa ukuba ukunyanga i-tumor sisiqingatha kuphela sedabi; ukulawula isifo sesibindi esisisiseko kubalulekile ngokulinganayo. Le ndlela "yolawulo lwekhosi yonke" iqinisekisa ukuba indawo yesibindi ayikhuthazi ukukhula komhlaza omtsha.

UNyango olunyanzelekileyo lweAntiviral

Ngenxa yokuba uninzi lwe umhlaza wesibindi iimeko e China zinxulunyaniswa Hepatitis B Virus (HBV), unyango antiviral ubomi bonke non-negotiable. Izikhokelo zigunyazisa ukusetyenziswa kwe-nucleos (t) i-ide analogues enamandla kunye nemiqobo ephezulu yokumelana, njenge-Entecavir okanye i-Tenofovir. Ukucinezela ukuphindaphinda kwentsholongwane akukhuseli kuphela ukusebenza kwesibindi kodwa kunciphisa ngokuthe ngqo umngcipheko wokuphindaphinda komhlaza.

Kwizigulane ze-Hepatitis C (HCV), ii-antivirals ezisebenza ngokuthe ngqo (DAAs) zinconywa, nangona ubungqina obuninzi bufunekayo ukuze kuqinisekiswe impembelelo yabo ethile ekukhuseleni ukuphindaphinda emva kokuhlinzwa xa kuthelekiswa nonyango lwe-HBV.

Indima yeTraditional Medicine yaseTshayina

Iyeza elidityanisiweyo liyaqhubeka lidlala indima kwindawo yonyango yaseTshayina. Imvumelwano incoma i-Huaier Granule kwizigulane emva kokutshatyalaliswa okukhulu. Uqwalaselo lwezonyango lucebisa ukuba lunokunceda ukuthintela ukuvela kwakhona kunye nokwandisa ukusinda ngokubanzi, ukusebenza njengonyango oluxhasayo ecaleni konyango oluqhelekileyo.

Imigangatho ekwinqanaba eliphezulu kunye neZigqibo zokuThatha iZigqibo

Ngaphandle konyango oluthile, indlela yokwenza isigqibo ngesicwangciso sonyango nayo iye yaphuculwa. Inguqulelo ye-2026 ye-Barcelona Clinic ye-Liver Cancer (BCLC) inkqubo yesiteji, eyamkelwa ngokubanzi e-China, ngoku idibanisa isakhelo sokwenza izigqibo esaziwa ngokuba yi-CUSE.

Isakhelo seSigqibo se-CUSE

I-CUSE imele ukuntsonkotha, ukungaqiniseki, ukuzithoba, kunye neemvakalelo. Esi sikhokelo sikhokela amaqela emfundo ezininzi ukuba athathele ingqalelo imilinganiselo emine ebalulekileyo:

• Ukuntsokotha: Ukuvuma uhlobo oluninzi lwesifo kunye neendlela zonyango ezikhoyo.
• Ukungaqiniseki: Ukujongana nokungacaci kwe-prognostic kunye nokuvela kobungqina bezonyango.
• Ukuthobela: Ukuhlonipha ukhetho lomntu ngamnye koogqirha kunye nezigulana.
• Uvakalelo: Ukuqwalasela amava exesha elidlulileyo, izinto ozilindeleyo, neenkolelo zobuqu.

Ngokudibanisa le miba yabantu kunye nobungqina beklinikhi, isakhelo se-CUSE siqinisekisa ukuba izigqibo zonyango zijolise kwisigulane ngokwenene, zihamba ngaphaya kwe-algorithms engqongqo kwizicwangciso zokhathalelo lomntu.

Uhlaziyo kwi-BCLC Staging Recommendations

Uhlaziyo luka-2026 BCLC luzisa utshintsho oluninzi oluthile:

• Inqanaba 0/A: I-Stereotactic Body Radiation Therapy (SBRT) kunye neTransarterial Radioembolization (TARE) ngoku zivunywa njengeendlela zonyango ezihambisana notyando kunye nokukhupha isisu.
• Inqanaba B: Izikhokelo zilumkisa ukuba ubungqina obukhoyo abunelanga ukucebisa ngokuqhelekileyo ukudibanisa unyango olungenelelayo kunye nonyango lwenkqubo kuzo zonke izigulane zesigaba esiphakathi.
• Inqanaba C: I-Immunotherapy edityaniswe nonyango olujoliswe kuyo imiselwe ngokuqinileyo njengomgangatho wokuqala wokhathalelo.

Uhlalutyo lokuthelekisa kwiiNdlela zoNyango

Ukunceda izigulana kunye neentsapho ziqonde ukhetho, le theyibhile ilandelayo ithelekisa amayeza aphambili acetyiswayo ngo-2026.

ISikhokelo seNyathelo ngeNyathelo kukhathalelo lwasemva kotyando ngo-2026

Ukuhamba uhambo lwasemva kokusebenza kunokuba nzima. Ngokusekwe kwimvumelwano yamva nje, nantsi indlela elungelelanisiweyo yezigulane ezihambayo umhlaza wesibindi unyango e China.

• Inyathelo loku-1: Uvavanyo lweSicwangciso soMngcipheko. Ngokukhawuleza emva kotyando, ingxelo ye-pathology ihlalutyelwe kwizinto ezinobungozi obuphezulu njenge-MVI, ubukhulu be-tumor, kunye nebakala lokwahlula. Oku kugqiba indlela yonyango elandelayo.
• Inyathelo lesi-2: Ukuqaliswa koNyango oluSisiseko. Zonke izigulana, nokuba zisemngciphekweni, ziqala okanye ziqhubeke nonyango lwe-antiviral ukuba i-HBV/HCV ine-HIV. Inkxaso yokusebenza kwesibindi ilungiselelwe.
• Inyathelo lesi-3: Ukukhethwa kweQhinga le-Adjuvant.
  • Izigulana ezinomngcipheko ophantsi: Ukubeka iliso rhoqo rhoqo kwiinyanga ezi-3-6.
  • Izigulane ezinobungozi obuphezulu: Ingxoxo ye-systemic therapy (ICI / TKI) kunye / okanye unyango lwendawo (TACE / HAIC / Radiotherapy).
• Inyathelo lesi-4: Ukuphunyezwa koNyango oluDityanisiweyo. Ukuba kubonisiwe, amayeza enkqubo yenkqubo ayaqaliswa, rhoqo edityaniswe nongenelelo lwengingqi olufana ne-TACE kwinyanga enye emva kokuphuma.
• Inyathelo lesi-5: UkuJonga uKhuseleko. Ukuhlolwa rhoqo kwityhefu yeziyobisi, kubandakanywa i-enzymes yesibindi, umsebenzi we-thyroid, kunye neempawu ze-pneumonitis okanye i-colitis.
• Inyathelo lesi-6: Ukubek' esweni ixesha elide. Izigulana ezisemngciphekweni omkhulu zifumana uvavanyo lwe-imaging kunye ne-biomarker qho kwiinyanga ezi-3. Ukubeka iliso okukwinqanaba eliphezulu njenge-ctDNA kunokusetyenziswa apho kukho khona.

Ukuqwalaselwa kweendleko kunye noKhuseleko lwe-Inshurensi

Ukufikelela kunyango olukumgangatho ophezulu yeyona nto ixhalabisa izigulane. Ngo-2026, imeko yezemali ye umhlaza wesibindi unyango e China luphuculwe kakhulu ngenxa yohlaziyo inshorensi yesizwe.

Uhlaziyo lwembuyekezo ye-inshurensi

Uphuhliso olungundoqo kukuqukwa kwee-PD-1 inhibitors ezininzi eziphuhliswe ekhaya kuLuhlu lwembuyekezo yeziyobisi yeSizwe (NRDL). Amachiza afana neFinolimab kunye nabanye baye babona izalathiso zabo zandisiwe ukugubungela umhlaza wesibindi, zibenza bafikeleleke kwisigulana esiqhelekileyo. Eli nyathelo liye lanciphisa kakhulu iindleko eziphuma epokothweni ze-immunotherapy, eyayifudula ibiza kakhulu.

Ukongeza, unyango olujoliswe kuyo kunye nezinye iinkqubo zongenelelo lwasekhaya ziphathwa phantsi kwe-inshorensi yonyango esisiseko. Umlinganiselo ochanekileyo wembuyekezo uyahluka ngokwengingqi kunye nohlobo oluthile lwe-inshurensi, kodwa imeko ibhekiselele kukhuseleko olubanzi lwezonyango ezitsha ezingqiniweyo zokwandisa ubomi.

IiNdleko eziqikelelweyo

Ngelixa iindleko ezithile zihluka ngokwesibhedlele kunye nommandla, izigulane kufuneka zilindele iindleko ezinxulumene noku:

• Iindleko zeziyobisi: Yehliswa kakhulu kumachiza afakwe kwi-inshorensi; Amachiza asuka kwamanye amazwe angaxhaswanga ahlala ephezulu.
• Iindleko zeNkqubo: I-TACE, i-HAIC, kunye ne-radiotherapy ibandakanya ukulaliswa esibhedlele kunye neentlawulo zobugcisa, ezihlawulwa kakhulu yi-inshurensi.
• Iindleko zokubeka iliso: Ukuhlolwa rhoqo kwe-CT/MRI kunye novavanyo lwegazi luyindleko eqhubekayo.

Izigulana zicetyiswa ukuba zidibane noonontlalontle basesibhedlele okanye abaququzeleli beinshorensi ukuze bandise izibonelelo zabo. Izibhedlele ezininzi ezikumgangatho ophezulu kwizixeko ezinjengeShanghai kunye neBeijing zinikezele amasebe ukunceda ngamabango e-inshurensi kunye neenkqubo zoncedo.

Ukufumana iSibhedlele esiLungileyo kunye neNgcali

Ukukhetha iziko lezonyango elichanekileyo kubalulekile kwiziphumo ezizezona zilungileyo. I-China inamaziko amaninzi akumgangatho wehlabathi asebenza nge-hepatobiliary oncology. "I-China Innovation Alliance ye-Hepato-Biliary Cancer," iqaliswe kutshanje, idibanisa amaziko ezonyango aphezulu angama-20 ukulungelelanisa ukunakekelwa nokukhuthaza uphando.

Amaziko aphezulu oNyango lomhlaza wesibindi

Izibhedlele ezininzi zidume ngobungcali bazo ekuphumezeni izikhokelo zemvumelwano ka-2026:

• Isibhedlele saseZhongshan (iYunivesithi yaseFudan, eShanghai): Ikhokelwe ngabafundi abanjengoFan Jia kunye noZhou Jian, eli ziko linguvulindlela wokufakelwa kwesibindi, uqhaqho loqhaqho, kunye nophando lonyango lwe-adjuvant. Idlale indima ephambili ekuyileni imvumelwano ka-2026.
• Isibhedlele saseBeijing Tsinghua Changgung: Iyaziwa ngeendlela zayo ezintsha, ezibandakanya i-Yttrium-90 radioembolization kunye neqela le-multidisciplinary (MDT) imodeli.
• ISibhedlele soMhlaza iZiko lezoNyango zaseTshayina (eBeijing): Inkokeli kulingo lonyango lwenkqubo kunye nokhathalelo olubanzi lwe-oncology.
• Isibhedlele sase-West China (iYunivesithi yaseSichuan): Ibonelela ngokhathalelo olukhethekileyo kwizigulana entshona China kunye nobuchule obuphambili botyando kunye nokungenelela.

Yintoni omawuyijonge esibhedlele

Xa ufuna unyango, izigulane kufuneka ziqinisekise ukuba isibhedlele siyanikezela:

• Uthethwano lweQela leeNgcaciso ezininzi (MDT): Uqinisekisa igalelo elivela koogqirha botyando, ii-oncologists, ii-radiologists, kunye neengcali zezifo.
• Ukufikelela kwiiMvavanyo zoNyango: Amathuba okufumana unyango lwesizukulwana esilandelayo phambi kokuba afumaneke ngokubanzi.
• Izixhobo zokuxilonga ezikwinqanaba eliphezulu: Ubukho bokujongwa kwe-ctDNA kunye nemifanekiso enesombululo esiphezulu.
• Iimodeli zokhathalelo oludityanisiweyo: Inkxaso yonyango lwe-antiviral, isondlo, kunye neengcebiso zengqondo.

IiPros and Cons of Modern Adjuvant Therapies

Ngelixa ukuqhubela phambili ngo-2026 kuyathembisa, kubalulekile ukuvavanya izibonelelo ngokuchasene nezinto ezinokuthi zibe khona.

• Izinto eziluncedo:
  • Ukusinda okuPhuculweyo: Ukongezwa okubalulekileyo kwi-Relapse-Free Survival (RFS) kunye nokusinda ngokubanzi (OS) kumaqela asemngciphekweni omkhulu.
  • Ukwenza okuthandwa nguwe: Unyango lulungiselelwe ngokusekelwe kwiimpawu ezithile ze-pathological kunye neeprofayili zofuzo.
  • Ukuphindaphinda okuNciphisiweyo: Ukupheliswa ngokukhawuleza kwe-micrometastases kwehlisa ithuba lokubuya kwangoko komhlaza.
  • Inkxaso ye-inshurensi: Ukufikeleleka okukhulu ngenxa yemigaqo-nkqubo yembuyekezo yesizwe.
• Izinto ezingeloncedo:
  • Iziphumo ebezingalindelekanga: I-Immunotherapy inokubangela iziganeko ezimbi ezinxulumene ne-immune ezichaphazela isibindi, imiphunga, okanye intliziyo. Amachiza ekujoliswe kuwo anokubangela uxinzelelo lwegazi okanye isifo sonyawo lwezandla.
  • Ukuntsokotha: Ukulawula unyango oludibeneyo lufuna amaqela onyango anamava kunye nokubeka iliso rhoqo.
  • Impendulo eguquguqukayo: Ayizizo zonke izigulane ezisabelayo kwi-immunotherapy; ii-biomarkers ukuqikelela impendulo zisavela.
  • Umthwalo wemali: Ngaphandle kwe-inshurensi, ezinye iindibaniselwano zenoveli okanye iindleko zononophelo ezixhasayo zisenokubaluleka.

Izalathiso zexesha elizayo kunye neeNdlela zoPhando

Intsimi ye umhlaza wesibindi unyango lunamandla. Ukujonga ngaphaya kuka-2026, iindawo ezininzi zilungele ukuqhubela phambili. Ukusekwa kogcino-lwazi lwesizwe ngamaqumrhu afana neChina Innovation Alliance yeHepato-Biliary Cancer iya kukhawulezisa ukufunyanwa kwedatha.

Impilo yeDijithali kunye ne-AI Integration

I-Artificial Intelligence isanda kusetyenziswa ukuqikelela imingcipheko ephindayo kunye nokwandisa izicwangciso zonyango. Iiplatifti zedijithali ziququzelela ukubeka iliso kude, ukuvumela izigulane ukuba zichaze iimpawu ngexesha langempela, elinceda ekuboneni kwangaphambili iziganeko ezimbi. Umxholo othi "inombolo yokuxhotyiswa kobukrelekrele" ugxininiswe kwiintlanganiso zonyaka zamva nje zezemfundo ubonisa olu tshintsho lubhekiselele kukhathalelo lobugcisa.

IiThagethi zoNyango zeNoveli

Uphando luyaqhubeka kwiithagethi ezintsha ngaphaya kwe-PD-1/VEGF axis yangoku. Ii-antibodies ze-Bispecific, unyango lweeseli ze-CAR-T ezilungiselelwe amathumba aqinileyo, kunye nezitofu zokugonya zonyango zikwizigaba ezahlukeneyo zophuhliso lwezonyango. Injongo kukuguqula iithumba "ezibandayo" zibe "zishushu" eziphendula ngakumbi kwi-immunotherapy.

Intsebenziswano yehlabathi

Abaphandi baseTshayina basebenzisana ngokukhutheleyo nabalingane bamazwe ngamazwe. Uphononongo lwamaziko amaninzi olubandakanya amaziko asuka kumazwe amaninzi luya luxhaphaka, luqinisekisa ukuba imigangatho yonyango e-China ihambelana neendlela ezingcono zehlabathi ngelixa kujongwa iimpawu ezizodwa ze-epidemiological zendawo, ezifana nokuxhaphaka okuphezulu kwe-HBV.

Ukuqukumbela

Unyaka ka-2026 uphawula ixesha lenguqu umhlaza wesibindi unyango e China. Ngokukhululwa kwemvumelwano ehlaziyiweyo yeengcali kunye nokudityaniswa kweenkqubo eziphambili zamanqanaba, izigulane ngoku zifikelela kwiindlela ezichanekileyo, ezisebenzayo, kunye nezomntu ngamnye. Ukutshintshela ekudibaniseni i-systemic immunotherapy kunye nongenelelo lwasekhaya kunika ithemba elitsha lokunciphisa amazinga aphezulu okuphindaphinda emva kotyando.

Eyona nto iphambili kule nkqubela phambili kukugxininiswa kwi-stratification yomngcipheko, ukuqinisekisa ukuba izigulane ezinomngcipheko ophezulu zifumana unyango lwe-adjuvant aggressive ngelixa izigulane ezinobungozi obuphantsi ziphepha ubutyhefu obungeyomfuneko. Idityaniswe nolawulo oluluqilima lwe-antiviral kunye nokhuseleko lwe-inshurensi ephuculweyo, imbonakalo yabaguli abanomhlaza wesibindi iqaqambile kunangaphambili. Ngokusebenzisa ubuchule bamaziko onyango aphezulu kunye nokuthobela izikhokelo zamva nje, izigulana zinokuhamba uhambo lwazo lonyango ngokuzithemba kunye nethemba.

Njengoko uphando luqhubeka nokuvela kunye nobuchwepheshe obutsha buvela, intsebenziswano phakathi kweeklinikhi, abaphandi, kunye nezigulana ziya kuhlala ziqhuba uphuculo oluqhubekayo kwimpilo kunye nomgangatho wobomi. Kuba nabani na ochaphazelekayo ngu umhlaza wesibindi, ukuhlala unolwazi malunga nolu phuhliso lwamva nje kunye nokufuna ukhathalelo kumaziko akhethekileyo lelona nyathelo libalulekileyo kwisiphumo esiyimpumelelo.